Forus Therapeutics News and Activities

Forus Therapeutics is owned by PharmaEssentia.

PharmaEssentia is a company listed under the stock ticker 6446 (TW).

PharmaEssentia has a direct presence in 3 countries.

PharmaEssentia has 4 subsidiaries including Forus Therapeutics, PharmaEssentia Innovation Research Center and PharmaEssentia Japan.

They are in:

• Biotechnology60%
• Pharmaceuticals40%

Acquisition, funding and merger involving PharmaEssentia.

• PharmaEssentia has acquired Forus Therapeutics (posted on June 18 2026).

View the org chart displaying its 6 main executives

Most searched biographies at Forus Therapeutics

• Kevin Leshuk, Chief Executive Officer
• Diane Brown, Medical and Scientific Affairs Director
• Dana Packer, Sales and Marketing Director

Create your alert
to follow the executive moves at Forus Therapeutics.

PharmaEssentia has 2,411 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Obsidian Therapeutics has filed its IPO. Its stock ticker will be OBX. (posted on June 18 2026).
• PharmaEssentia has acquired Forus Therapeutics (posted on June 18 2026).
• Biogen has announced the acquisition of RayThera  (posted on June 18 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by Forus Therapeutics

• News | FORUS Therapeutics

Social media about Forus Therapeutics

• Forus Therapeutics on Wikipedia, Google News & Yahoo Finance
• Forus Therapeutics on LinkedIn, X (Twitter) & YouTube